Prognostic stratification of patients with AJCC 2018 pN1 disease in stage III oral squamous cell carcinoma

Ming-Hsien Tsai1,2,3, Hui-Ching Chuang1,2, Yu-Tsai Lin1,2,3, Tai-Lin Huang2,4, Fu-Min Fang2,5, Hui Lu1 and Chih-Yen Chien1,2,6*

Abstract

Background: Oral cancer with pT1-3N1 without extracapsular extension of the lymph node is classified as stage III according to the eighth edition of the AJCC staging system. Outcomes of a subgroup of patients classified as having stage III oral cancer with single nodal metastasis are observed to be various clinically. Therefore, such clinical outcomes for subgroup analyses in this cohort are necessary.

Methods: Patients with pT1-3N1 (based on the eighth edition of the AJCC staging system) oral cancer who underwent surgery between 2007 and 2016 were enrolled retrospectively for survival analyses.

Results: A total of 105 patients—including 28 patients with pT1N1 disease and 77 patients with pT2-3N1 disease—participated in the study. Pathological T classification was the only statistically significant prognosticator according to univariate analysis. The patients with pT1N1 disease showed better 5-year overall survival (OS), disease specific survival (DSS), and disease free survival (DFS) than those with pT2-3N1 disease (pT1N1 vs pT2-3N1, OS: 96.4% vs 72.2%, p = 0.004; DSS: 96.4% vs 77.3%, p = 0.021; DFS: 84.6% vs 62.3%, p = 0.023). Besides, there was no potential clinico-pathological confounder which is significant associated with different pathological T classifications in this unique cohort.

Conclusions: Patients in the pT1N1 subgroup have significantly favorable prognosis than those with pT2-3N1 disease. Down-staging and reclassifying pT1N1 subgroup patients with oral cancer may be considered in tumor staging.

Keywords: Single nodal metastasis, N1, Stage III, Oral cancer, Prognosis

*Correspondence: cychien3965@adm.cgmh.org.tw

1 Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Oral squamous cell carcinoma (OSCC) is a common malignant tumor in the head and neck region that accounts for 8.0% of all new cancers diagnosed and 6.3% of all cancer deaths annually in Taiwan [1]. Pathological nodal metastases are a well-known poor prognostic factor in patients with OSCC [2]. The presence of extranodal extension (ENE) was also recognized as a more adverse factor in patients with pathologically nodal metastases [3]. The newest American Joint Committee on Cancer (AJCC) staging system (eighth edition) introduced significant changes in terms of ENE classification to determine the N-classification of patients with OSCC [4]. The presence of ENE in previous pathologically confirmed pT1-3N1, stage III disease, would be upstaged to pT1-3N2a, stage IVa disease, respectively.

Given the upstaging of positive nodal status with ENE to stage IV disease in OSCC according to the AJCC eighth edition TNM staging system, the prognosis of stage III OSCC patients with pN1 disease is clinically fair. An improved prognostic stratification can help refine and tailor treatments at the individual level. Therefore, a detailed subgroup analysis of stage III OSCC patients with pN1 disease is necessary. We aimed to investigate the prognostic impact of different clinico-pathological factors in this subgroup of patients according to the AJCC eighth edition TNM staging system.

Graphical Abstract

PROGNOSTIC STRATIFICATION OF PATIENTS WITH AJCC 2018 PNI1 DISEASE IN STAGE III ORAL SQUAMOUS CELL CARCINOMA
Tsai MH, Chuang HC, Lin YT, Huang TL, Fang FM, Lu H, Chien CY

BACKGROUND
To investigate the prognostic impact of different clinico-pathological factors in a subset of patients with stage III oral cavity squamous cell carcinoma (OSCC) with pN1 disease (AJCC 8th edition TNM staging)

METHODS
Retrospective Study
Patients with pT1-3N1 oral cavity cancer

RESULTS
(28 patients) pT1N1 disease
Overall survival 96.4%
Disease specific survival 96.4%
Disease free survival 84.6%

105 patients
(77 patients) pT2-3N1 disease
Overall survival 72.2%
Disease specific survival 77.3%
Disease free survival 62.3%

Patients in the pT1N1 subgroup have a significantly more favorable prognosis than those with pT2-3N1 disease. Down-staging & reclassifying pT1N1 subgroup patients with oral cancer may be considered in oral cavity tumor staging
Materials and methods

Study population
Consecutive 1,476 treatment naive patients with OSCC were enrolled from the head and neck database, and they underwent upfront surgery with ipsilateral or bilateral neck dissections at Kaohsiung Chang Gung Memorial Hospital, Taiwan, between January 2007 and March 2016. The tumors were restaged according to the AJCC eighth edition TNM staging system, and the updated pN classification was as follows: pN0 (n = 1,018; 69%), pN1 (n = 127; 8.6%), pN2 (n = 139; 9.4%), and pN3b (n = 192; 13%). Patients who (a) did not receive curative intent surgery with neck dissection as an initial treatment strategy, (b) had any other previous cancer history, (c) had non-squamous cell carcinoma, and (d) had synchronous double cancer history were excluded from the study. In total, 105 patients were enrolled in our study cohort, including 28 patients with pT1N1 disease, 49 patients with pT2N1 disease, and 28 patients with pT3N1 disease. We also enrolled patients with pT2N0 disease from this cancer database during this period who served as the reference for outcome comparison.

Neck dissections and postoperative adjuvant therapy
In general, classic radical or modified radical neck dissections (level I–IV) were performed in patients with clinically positive lymph nodes, whereas neck dissections (level I–III) were used in clinically node-negative patients. Patients were treated with bilateral neck dissections if the primary tumor reached or crossed the midline sagittal plane of the oral cavity. Treatment was mostly based on the American National Comprehensive Cancer Network (NCCN) guidelines. All the patients included in this study had detailed clinical and pathologic information, including adverse pathologic features, available for review. All the included patients completed the treatment strategy advised by the multidisciplinary team. The outcomes of interest investigated including overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS).

Table 1 Patient characteristics (n = 105)

| Characteristics                      | Value | %    |
|--------------------------------------|-------|------|
| Median age [range], yr               | 54 [32, 77] |
| Median Follow up period [range], month | 69.5 [6.2, 154.1] |
| Sex                                  |       |      |
| Male                                 | 91    | 86.7 |
| Female                               | 14    | 13.3 |
| Cancer location                      |       |      |
| Tongue                               | 41    | 39.0 |
| Buccal                               | 37    | 35.2 |
| Other subsites                       | 27    | 25.7 |
| pT classification                    |       |      |
| pT1                                  | 28    | 26.7 |
| pT2                                  | 49    | 46.7 |
| pT3                                  | 28    | 26.7 |
| Histological grade                   |       |      |
| WDSCC†                                | 38    | 36.2 |
| MDSCC‡                               | 62    | 59   |
| PDSCC§                               | 5     | 4.8  |
| Perineural invasion                  |       |      |
| Positive                             | 34    | 32.4 |
| Negative                             | 71    | 67.6 |
| Lymphovascular invasion              |       |      |
| Positive                             | 23    | 21.9 |
| Negative                             | 82    | 78.1 |
| Surgical margin                      |       |      |
| < 4 mm                               | 23    | 21.9 |
| ≥ 4 mm                               | 82    | 78.1 |
| Median of depth of invasion [range], mm | 8 [1, 19] |
| Median value of positive node size [range], cm | 1.3 [0.2, 3] |
| Recurrence                           |       |      |
| Yes                                  | 35    | 33.3 |
| No                                   | 70    | 66.7 |

† WDSCC, well differentiated squamous cell carcinoma
‡ MDSCC, moderately differentiated squamous cell carcinoma
§ PDSCC, poorly differentiated squamous cell carcinoma

Significant. This study was approved by the Medical Ethics and Human Clinical Trial Committees at Chang Gung Memorial Hospital. (Ethical Application Reference number:202101147B0).

Results
A total of 105 patients with pN1 stage III OSCC were enrolled in this study. The clinical characteristics of the patients are summarized in Table 1. The median age of the patients was 54 years (range 32–77). The study sample included 91 (86.7%) male patients and 14 (13.3%) female patients. In tumor differentiation, most of the patients had moderately differentiated carcinoma (n = 62, 59%), followed by well-differentiated carcinoma (n = 38,
36.2%) and poorly differentiated carcinoma (n = 5, 4.8%). The median of the greatest tumor size was 22 mm (range 6–55), and the median of the depth of invasion (DOI) was 8 mm (range 1–19). Perineural invasion and lymphovascular invasion were reported in 32.4% and 21.9% of the patients, respectively. In total, 97 patients (92.4%) received ipsilateral neck dissection, while only 8 patients (7.6%) underwent bilateral neck dissection because of the cross midline of the tumor. Thirty-seven patients had clinical N0 disease and received neck dissections. Furthermore, 35 patients received adjuvant radiotherapy after surgery, 17 patients received adjuvant concurrent chemoradiotherapy, and 53 patients preferred not to receive any postoperative adjuvant therapy. Our study cohort included 28 patients (26.7%) with pT1N1 disease, 49 patients (46.6%) with pT2N1 disease, and 28 patients (26.7%) with pT3N1 disease. The patients were followed up for a median of 69.5 months in this cohort. Tumor recurrence was observed in 35 (33.3%) patients, including local, regional, locoregional recurrence and distant metastasis occurred in 11, 16, 4, and 4 patients, respectively.

For pT classification, we found that patients in pT1N1 group had favorable outcomes than pT2N1 and pT3N1 groups (pT1N1 vs. pT2N1, OS: p = 0.009; DSS: p = 0.035; DFS: p = 0.039; pT1N1 vs. pT3N1, OS: p = 0.001; DSS: p = 0.013; DFS: p = 0.023). However, pT2N1 group and pT3N1 group had very closed trend of Kaplan Meier survival curves (pT2N1 vs. pT3N1, OS, p = 0.252; DSS: p = 0.555; DFS: p = 0.717) (See Additional file 1: Table S1). Under this circumstance, we categorized our cohort into pT1N1 and pT2N1 as pT classification risk factor for further analysis.

The five-year survival rates of OS, DSS, and DFS were estimated for all clinico-pathological variables listed in Table 2. These results showed that pT1N1 disease was significantly associated with higher rates of five-year OS, DSS, and DFS compared with pT2-3N1 disease in univariate analysis (OS: p = 0.004, DSS: p = 0.021, and DFS: p = 0.023). The Kaplan–Meier curves of each strata (pT1N1 vs. pT2-3N1) was shown in Fig. 1. We also examined the relationships between the pT classification and other clinico-pathological factors. The pT classification did not have significant association with age, histologic grade, PNI, LVI, surgical margin, positive nodal size and received adjuvant therapy or not (all p > 0.05) (See Additional file 2: Table S2).

Role of adjuvant therapy in subgroups of pN1 disease
In this cohort, no significant difference in survival was observed (all p > 0.05) between patients who received adjuvant therapy and those who did not in both pT1N1 and pT2-3N1 strata. In pT2-3N1 subgroup, the survival outcomes for the surgery-with-adjuvant-therapy patients and the surgery-alone patients had no significant difference (OS: 80.1% vs. 63.2%, p = 0.671, DSS: 82.9% vs. 70.6%, p = 0.182, and DFS: 68.2% vs. 55.6%, p = 0.175). Similar results were observed for pT1N1 stratum, the survival rates for surgery-with-adjuvant-therapy group vs. the surgery-alone group were, OS: 100% vs. 94.1%, p = 0.421; DSS: 100% vs. 94.1%, p = 0.421, and DFS: 90.9% vs. 80.2%, p = 0.56 (Table 3).

Five-year OS, DSS, and DFS in OSCC patients with pT1N1 and pT2N0 disease
Given the significantly better survival of pT1N1 disease patients among those with stage III OSCC, another cohort of patients with pathologically confirmed T1N1 disease (n = 28) and T2N0 disease (stage II, n = 270) from our cancer database between January 2007 and March 2016 were enrolled for comparison in terms of survival rates. The outcomes showed no significant differences in terms of five-year OS, DSS, and DFS between pT1N1 (n = 28) and pT2N0 (n = 270) patients (OS: 96.4% vs. 84.8%, p = 0.128; DSS: 96.4% vs. 93.7%, p = 0.578; DFS: 85.7% vs. 88.5%, p = 0.63). The Kaplan–Meier curves of OS, DSS, and DFS in patients with pT1N1 and pT2N0 disease (according to the AJCC eighth edition TNM staging system) were represented in Fig. 2.

Discussion
The AJCC eighth edition TNM staging system recommended changes in the primary tumor and nodal staging of OSCC, including the DOI to the pT classification and ENE to the pN classification [4]. Although a significant improvement in precision in staging was observed, some limitations of the AJCC staging system were not addressed. Matos et al. [5] compared the AJCC seventh and eighth editions for OSCC in a cohort of 298 patients and found that patients upstaged by the DOI improved discrimination among pT1, pT2, and pT3 for DFS and OS; Garcia et al. [6] compared the pathological lymph node staging systems for multiple subsites of head and neck SCC, of which 270 patients had OSCC. They also found that patients upstaged by ENE had significantly worse cancer-specific survival than those who were not. However, the outcomes in the subgroup of stage III OSCC with pN1 disease (pT1N1, pT2N1, and pT3N1) varied clinically.

To the best of our knowledge, this study is the first to explore outcomes in pN1 with stage III OSCC among patients with different T classifications according to the AJCC eighth edition TNM staging system. A subgroup analysis of patients with stage III OSCC revealed that the clinical outcomes of pT1N1 disease showed lower HRs in OS, DSS, and DFS than the other groups (OS: p = 0.021,
Table 2  Univariate analysis of factors impacting survival (n = 105)

| Variable                  | Number | 5-year OS\(^{(\%)}\) | p  | 5-year DSS\(^{(\%)}\) | p  | 5-year DFS\(^{(\%)}\) | p  |
|---------------------------|--------|-----------------------|----|------------------------|----|------------------------|----|
| Sex                       |        |                       |    |                        |    |                        |    |
| Male                      | 91     | 77.2                  | 0.780 | 80.8                  | 0.233 | 66.6                  | 0.310 |
| Female                    | 14     | 85.7                  |        | 92.9                  |        | 78.6                  |        |
| Age                       |        |                       |    |                        |    |                        |    |
| < 54                      | 50     | 85.7                  | 0.140 | 85.7                  | 0.134 | 71.9                  | 0.281 |
| ≥ 54                      | 55     | 71.8                  |        | 79.3                  |        | 65.0                  |        |
| Smoking habit             |        |                       |    |                        |    |                        |    |
| No                        | 19     | 73.3                  | 0.656 | 83.1                  | 0.606 | 68.0                  | 0.782 |
| Yes                       | 86     | 79.7                  |        | 82.3                  |        | 68.3                  |        |
| Betelnut chewing          |        |                       |    |                        |    |                        |    |
| No                        | 22     | 71.0                  | 0.603 | 85.2                  | 0.511 | 72.4                  | 0.473 |
| Yes                       | 83     | 80.3                  |        | 81.5                  |        | 67.1                  |        |
| Alcohol drinking          |        |                       |    |                        |    |                        |    |
| No                        | 26     | 88.5                  | 0.213 | 96.0                  | 0.086 | 76.3                  | 0.331 |
| Yes                       | 79     | 75.2                  |        | 78.0                  |        | 65.6                  |        |
| pT classification         |        |                       |    |                        |    |                        |    |
| pT1                       | 28     | 96.4                  | 0.004\(^{*}\) | 96.4                  | 0.021\(^{*}\) | 84.6                  | 0.023\(^{*}\) |
| pT2-3                     | 77     | 72.2                  |        | 77.3                  |        | 62.3                  |        |
| Histological grade        |        |                       |    |                        |    |                        |    |
| WDSCC\(^{¶}\)            | 38     | 83.9                  | 0.743 | 86.5                  | 0.839 | 68.3                  | 0.309 |
| MDSCC\(^{∥}\)            | 62     | 75.0                  |        | 80.1                  |        | 70.6                  |        |
| PDSCC\(^{#}\)            | 5      | 80.0                  |        | 80.0                  |        | 40.0                  |        |
| Depth of invasion         |        |                       |    |                        |    |                        |    |
| < 8 mm                    | 52     | 84.1                  | 0.121 | 88.5                  | 0.256 | 74.6                  | 0.351 |
| ≥ 8 mm                    | 53     | 73.0                  |        | 76.6                  |        | 62.1                  |        |
| Perineural invasion       |        |                       |    |                        |    |                        |    |
| No                        | 71     | 77.7                  | 0.528 | 80.9                  | 0.405 | 64.3                  | 0.128 |
| Yes                       | 34     | 79.3                  |        | 85.3                  |        | 76.2                  |        |
| Lymphovascular invasion   |        |                       |    |                        |    |                        |    |
| No                        | 82     | 78.7                  | 0.953 | 81.2                  | 0.857 | 66.6                  | 0.621 |
| Yes                       | 23     | 77.7                  |        | 86.7                  |        | 73.9                  |        |
| Surgical margin           |        |                       |    |                        |    |                        |    |
| < 4 mm                    | 23     | 71.2                  | 0.279 | 71.2                  | 0.320 | 60.9                  | 0.364 |
| ≥ 4 mm                    | 82     | 80.1                  |        | 85.2                  |        | 70.3                  |        |
| Size of positive node     |        |                       |    |                        |    |                        |    |
| < 1.3 cm                  | 42     | 83.1                  | 0.431 | 88.1                  | 0.224 | 75.8                  | 0.182 |
| ≥ 1.3 cm                  | 63     | 75.1                  |        | 78.5                  |        | 63.3                  |        |
| Adjuvant therapy          |        |                       |    |                        |    |                        |    |
| No                        | 53     | 72.5                  | 0.801 | 78.1                  | 0.239 | 63.5                  | 0.270 |
| Yes                       | 52     | 84.3                  |        | 86.5                  |        | 73.0                  |        |

\(^{*}\) OS, overall survival; \(^{\dagger}\) DSS, disease specific survival; \(^{\ddagger}\) DFS, disease free survival

\(^{¶}\) WDSCC, well differentiated squamous cell carcinoma

\(^{∥}\) MDSCC, moderately differentiated squamous cell carcinoma

\(^{#}\) PDSCC, poorly differentiated squamous cell carcinoma
DSS: $p = 0.049$, and DFS: $p = 0.028$). We also found that prognosis of pT1N1 group and pT2N0 group didn’t have statistically significant difference. It provided the possibility of downstage for this unique subgroup patients, pT1N1, to stage II in the future staging system.

For OSCC patients with pN1 disease, the benefits of postoperative adjuvant therapy were still unclear. Chen et al. [7] analyzed 59 patients with pT1/pT2 with either pN0 or pN1 oral tongue squamous cell carcinoma, and they found improved five-year DSS in those who had undergone postoperative radiotherapy (PORT) compared with those had not after operation (81.2% vs. 53.0%; $p = 0.03$), but no difference in OS was observed (77.0% vs. 70.5%; $p = 0.36$). Shrime et al. [8] analyzed 1,539 patients in the Surveillance, Epidemiology, and End Results (SEER) database with only T1N1 and T2N1 OSCC, and they found that 78.6% of the patients had undergone PORT and that PORT was associated with improved five-year OS (54.2% vs. 41.4%; $p < 0.001$). Kao et al. [9] found no difference in five-year OS between pN1 OSCC patients who had and had not undergone PORT (38.7% vs. 36.0%; $p = 0.23$) using the SEER database. However, few studies have mentioned DOI and ENE status, which may alter staging according to the AJCC eighth edition staging system. In this cohort, OSCC patients with pN1 disease did not show significant alteration in survival related to postoperative adjuvant therapy. Interestingly, while we divided the study cohort into subgroups of pT1N1 and pT2-3N1 disease, patients with pT2-3N1 disease who had undergone adjuvant therapy had better oncologic outcomes than those who had not. No survival benefit of postoperative adjuvant therapy in pT1N1 disease was found.

Several limitations should be addressed in this study. First, this is a retrospective, single-institute study, and all the patients underwent surgical procedures at a single institution performed by different head and neck surgeons. Second, the case number in this study is limited. It may be the reason that none of the other adverse features such as DOI, PNI, LVI, margin status, and size of nodes were identified as significant prognosticator in this cohort. Besides, lack of multivariate analysis to adjust possible confounders was also another limitation of our study. Further multicenter studies are necessary to further confirm whether patients with pT1N1 disease have better clinical outcomes than those of other subgroups of stage III OSCC.

**Conclusions**

Our data revealed that patients with pT1N1 disease have more favorable prognoses than pN2-3N1 patients among those with stage III OSCC. Down-staging patients with pT1N1 disease, along with reclassification in terms of tumor stage, may be considered in the future.
Table 3  Univariate Analysis of adjuvant therapy or not Impacting Survival (n = 105)

| Variable | Number | 5-year OS† (%) | p   | 5-year DSS‡ (%) | p   | 5-year DFS§ (%) | p   |
|----------|--------|---------------|-----|----------------|-----|----------------|-----|
| pT1N1    |        |               |     |                |     |                |     |
| Without AT¶ | 17     | 94.1          | 0.421 | 94.1          | 0.421 | 80.2            | 0.560 |
| With AT  | 11     | 100.0         | 100.0 |               | 100.0 | 90.9            |     |
| pT2-3N1  |        |               |     |                |     |                |     |
| Without AT | 36     | 63.2          | 0.671 | 70.6          | 0.182 | 55.6            | 0.175 |
| With AT  | 41     | 80.1          | 82.9  |               | 82.9  | 68.2            |     |

† OS, overall survival; ‡ DSS, disease specific survival; § DFS, disease free survival; AT¶, adjuvant therapy

Fig. 2 Kaplan–Meier survival curves of OSCC patients with pT1N1 disease and pT2N0 disease. A Overall survival curves, B disease-specific survival curves, and C disease-free survival curves

Abbreviations
OSCC: Oral squamous cell carcinoma; ENE: Extranodal extension; AJCC: American Joint Committee on Cancer; NCCN: National Comprehensive Cancer Network; OS: Overall survival; DSS: Disease-specific survival; DFS: Disease-free survival; HR: Hazard ratio; CI: Confidence interval; PORT: Postoperative radiotherapy; SEER: Surveillance, Epidemiology, and End Results.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40463-022-00573-x.

Additional file 1: Table S1 Univariate analysis of different pT classification impacting survival.
Additional file 2: Table S2 Patient characteristics between pT1N1 and pT2-3N1 patients.

Acknowledgements
Not applicable.

Author contributions
MHT conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper. HCC, YTL and TLH performed the experiments, authored or reviewed drafts of the paper. FMF performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper. HL contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper. CYC conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the paper. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Medical Ethics and Human Clinical Trial Committees at Chang Gung Memorial Hospital. (Ethical Application Reference number: 202101147B0), and the written approval was waived.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 2 Kaohsiung Chang Gung Head and Neck Oncology Group, Cancer Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 3 College of Pharmacy and Health Care, Tajen University, Pingtung, Taiwan. 4 Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. 5 Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. 6 Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
References

1. Hsu WL, Yu KJ, Chiang CJ, Chen TC, Wang CP. Head and neck cancer incidence trends in Taiwan, 1980–2014. Int J Head Neck Sci. 2017;1(3):180–9.

2. Liao CT, Hsuie C, Lee LY, et al. Neck dissection field and lymph node density predict prognosis in patients with oral cavity cancer and pathological node metastases treated with adjuvant therapy. Oral Oncol. 2012;48:529–36.

3. Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer. 2001;92:3030–6.

4. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.

5. Matos LL, Dedivitis RA, Kulcsar MAV, de Mello ES, Alves VAF, Cernea CR. External validation of the AJCC Cancer Staging Manual, 8th edition, in an independent cohort of oral cancer patients. Oral Oncol. 2017;71:47–53.

6. Garcia J, Lopez M, Lopez L, et al. Validation of the pathological classification of lymph node metastasis for head and neck tumors according to the 8th edition of the TNM Classification of Malignant Tumors. Oral Oncol. 2017;70:29–33.

7. Chen TC, Wang CT, Ko JY, et al. Postoperative radiotherapy for primary early oral tongue cancer with pathologic N1 neck. Head Neck. 2010;32:555–61.

8. Shrime MG, Gullane PJ, Dawson L, et al. The impact of adjuvant radiotherapy on survival in T1–2N1 squamous cell carcinoma of the oral cavity. Arch Otolaryngol Head Neck Surg. 2010;136:225–8.

9. Kao J, Lavaf A, Teng MS, Huang D, Genden EM. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys. 2008;71:362–70.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.